<DOC>
	<DOC>NCT01455597</DOC>
	<brief_summary>This is an open-label extension study evaluating the long-term safety and efficacy of WC3011 in non-hysterectomized, healthy, postmenopausal women with vulvovaginal atrophy.</brief_summary>
	<brief_title>Evaluate Long-Term Safety and Efficacy WC3011</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Completed Study PR04409 Developed any of the following during StudyPR04409 or has begun taking hormone therapy other than WC3011: Hypersensitivity to estrogen and/or progestin therapy Known or suspected premalignant or malignant disease (except successfully treated skin cancers) Manifestation of or treatment for significant cardiovascular disease, stroke or ischemic attack Insulindependent diabetes mellitus Smoking ≥ 15 cigarettes daily Uncontrolled hypertension systolic blood pressure (BP) ≥ 160 mmHG or diastolic ≥ 95 mmHg</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Postmenopausal Women</keyword>
	<keyword>Vaginal Dryness</keyword>
	<keyword>Postmenopausal Vulvovaginal Atrophy</keyword>
</DOC>